Skip to main content

Table 1 LOI and MOI in hiPSCs

From: Stability of genomic imprinting in human induced pluripotent stem cells

   H19 IGF2 PEG3 PEG1 GTL2 KCNQ1 NDN LIT1
   (RsaI) (ApaI) (MnlI) (AflIII) (TaaI) (SmaI) (MboI) (RsaI)
Cell Passage gDNA cDNA gDNA cDNA gDNA cDNA gDNA cDNA gDNA cDNA gDNA cDNA gDNA cDNA gDNA cDNA
AM936EP P9 a/b a b - a - b - a/b a a - b - a/b a
AM-iPS -2 P13 a/b a b - a - b - a/b a a - b - a/b a
AM-iPS -2 P19 a/b a b - a - b - a/b a a - b - a/b a
AM-iPS -2 P35 a/b a b - a - b - a/b a a - b - a/b a
AM-iPS -3 P9 a/b a b - a - b - a/b a a - b - a/b a
AM-iPS -3 P21 a/b a b - a - b - a/b a a - b - a/b a
AM-iPS -3 P29 a/b b b - a - b - a/b a a - b - a/b a
AM-iPS -3 P36 a/b a b - a - b - a/b a a - b - a/b a
AM-iPS -7 P12 a/b a b - a - b - a/b a/b a - b - a/b a
AM-iPS -7 P22 a/b a b - a - b - a/b a/b a - b - a/b a
AM-iPS -7 P32 a/b a b - a - b - a/b a/b a - b - a/b a
AM-iPS -8 P13 a/b a b - a - b - a/b a a - b - a/b a
AM-iPS -8 P20 a/b a b - a - b - a/b a a - b - a/b a
AM-iPS -8 P37 a/b a b - a - b - a/b a a - b - a/b a
AM-iPS -20 P8 N.T. a N.T. - N.T. - N.T. - N.T. a N.T. - N.T. - N.T. a
AM-iPS -20 P11 a/b a b - a - b - a/b a a - b - a/b a
AM-iPS -20 P14 a/b a b - a - b - a/b a a - b - a/b a
AM-iPS -20 P16 a/b N.D. b - a - b - a/b a a - b - a/b a
AM-iPS -20 P32 a/b N.D. b - a - b - a/b a a - b - a/b a
PL551Ar P16 a/b a a/b a b - a/b N.D. b - b N.D. a - a -
PAE-iPS -05 P19 a/b a a/b N.D. b - a/b N.D. b - b - a - a -
PAE-iPS -05 P31 a/b a a/b N.D. b - a/b N.D. b - b - a - a -
PAE-iPS -11 P14 a/b a a/b N.D. b - a/b N.D. b - b - a - a -
PAE-iPS -11 P18 a/b a a/b N.D. b - a/b N.D. b - b - a - a -
PAE-iPS -11 P30 a/b a a/b N.D. b - a/b N.D. b - b - a - a -
MRC-5 - a/b N.D. b - a - b - a/b a/b a/b N.D. a/b N.D. a -
MRC-iPS -16 P30 a/b N.D. b - a - b - a/b ND a/b b a/b a a -
MRC-iPS -25 P6 a/b N.D. b - a - b - a/b ND a/b b a/b a a -
MRC-iPS -25 P30 a/b N.D. b - a - b - a/b ND a/b b a/b a a -
MRC-iPS -40 P11 a/b N.D. b - a - b - a/b ND a/b b a/b a a -
MRC-iPS -40 P30 a/b N.D. b - a - b - a/b ND a/b b a/b a a -
UtE1104 P9 a/b N.D. a - a/b a/b a/b b a/b a/b b N.D. b - a -
UtE-iPS -6 P20 a/b N.D. a - a/b a/b a/b a/b a/b a/b b - b - a -
UtE-iPS -6 P31 a/b b a - a/b a/b a/b a/b a/b a/b b - b - a -
UtE-iPS -11 P13 a/b N.D. a - a/b N.D. a/b a/b a/b a b N.D. b - a -
UtE-iPS -11 P20 a/b N.D. a - a/b N.D. a/b a/b a/b a/b b N.D. b - a -
UtE-iPS -11 P30 a/b N.D. a - a/b N.D. a/b a/b a/b a b - b - a -
Edom22 P5 b - a/b a/b a - a/b b b - a/b a a - a -
Edom-iPS -1 P27 b - a/b N.D. a - a/b b b - a/b a a - a -
hES 3 P29 a/b a b - a/b a a/b b b - a - a/b b a -
SEES 1 P10 a/b a a/b a a - b - a/b b a - a - a -
SEES 4 P9 a/b b a/b a a - b - b - a - a/b b a -
  1. A summary of LOI and MOI RFLP data for the 8 imprinted genes analyzed in 22 hiPSCs and 3 control hES cell lines. hiPSCs derived from extraembryonic amniotic membrane (AM-iPS), embryonic lung tissue (MRC-iPS), uterine endometrium (UtE-iPS), adult menstrual blood (Edom-iPS) and extraembryonic placental tissue (PAE-iPS). Samples were analyzed at the specified passage number. (-): not informative.